Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
The DOI matches its Crossref record.
Abstract
The anti-Tac mAb has been shown to bind to the p55 chain of the IL-2R, block IL-2 binding and inhibit T cell proliferation. A humanized form of anti-Tac (HAT) has been constructed that retains the binding properties of murine anti-Tac (MAT). These two mAb were evaluated in cynomolgus monkeys to compare relative immunogenicity and pharmacokinetic properties. Monkeys treated with HAT daily for 14 days exhibited anti-HAT antibody titers which were 5- to 10-fold lower than their MAT-treated counterparts and these antibodies developed later than in the MAT-treated monkeys. Two of four monkeys receiving a single injection of MAT developed anti-MAT antibodies, whereas none of four monkeys developed antibodies after a single treatment with HAT. In monkeys injected with either HAT or MAT daily for 14 days, the anti-antibody titers induced were inversely related to the amount of anti-Tac administered. Antibodies that developed against MAT were both anti-isotypic and anti-idiotypic, whereas those developed against HAT appeared to be predominantly anti-idiotypic. The pharmacokinetic properties, that is the half-life and area under the curve values, of HAT were also significantly different from those of MAT. The area under the curve values for HAT in naive monkeys were approximately twofold more than those for MAT, and the mean serum half-life of HAT was 214 h, approximately four- to fivefold more than MAT. These pharmacokinetic values were reduced in monkeys previously sensitized with HAT or MAT suggesting that the presence of anti-antibodies altered these parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 355
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R. (1999) · Transplantation · doi:10.1097/00007890-199901150-00019 · Cited by 302
Przepiorka, D., Kernan, N. A., Ippoliti, C., Papadopoulos, E. B., Giralt, S., Khouri, I., Lu, J.-G., Gajewski, J., Durett, A., Cleary, K., et al. (2000) · Blood · doi:10.1182/blood.v95.1.83 · Cited by 263
Metadata
- Authors
- Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R. S., Lin, P., Weber, D. V., & Spence, C.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1991-08
- Volume
- 147
- Issue
- 4
- Pages
- 1352-1359
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1934038313
- Cited by
- 103
- References
- 0
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. https://app.cochat.ai/papers/10.4049/jimmunol.147.4.1352
- The paper
- Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R. S., Lin, P., Weber, D. V., & Spence, C. (1991). Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. The Journal of Immunology. https://doi.org/10.4049/jimmunol.147.4.1352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.